James Brugarolas MD PhD
Genitourinary Oncology, Hematologic Oncology
Director, Kidney Cancer Program; Sherry Wigley Crow Endowed Chair in Cancer Research; Professor of Internal Medicine/ Hematology-Oncology, Cancer Biology, Genetics, Development and Disease at UT Southwestern Medical Center
Join to view full profile
5323 Harry Hines BoulevardDallas, TX 75390
Phone+1 214-645-4673
Fax+1 214-645-2542
Dr. Brugarolas is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
Clinical Expertise
- Kidney Neoplasms, Renal cell carcinoma, Urologic oncology, Hematologic oncology
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2003
Duke University HospitalResidency, Internal Medicine, 1998 - 2001
Massachusetts Institute of TechnologyPhD, Biology, 1993 - 1998
Universidad de Navarra Faculty of MedicineClass of 1993
Certifications & Licensure
TX State Medical License 2006 - 2028
MA State Medical License 2002 - 2007
NC State Medical License 1998 - 2004
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Elected member Association of American Physicians, 2025
- Principal Investigator, Kidney Cancer Specialized Program of Research Excellence (SPORE) National Cancer Institute
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017
Publications & Presentations
PubMed
- Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank.Pavlos Msaouel, Salvatore La Rosa, Edwin Jason Abel, Laurence Albiges, Pedro C Barata
Urologic Oncology. 2026-09-12 - Lactate-Activated GPR132 Signaling Drives a Tumor Microenvironmental Autocrine Metabolic Loop in Kidney Cancer.Dazhi Wang, Timothy M Horton, Kyutae David Lee, Ifeanyichukwu Chinedu Ogobuiro, Fatemeh Vatankhah
Cancer Research. 2026-09-02 - Clinical Outcomes, Treatment Patterns, and Molecular Heterogeneity of TFE3-Rearranged Renal Cell Carcinoma: A Multicenter Real-World Study.Shuxuan Zhu, Siqi Zhou, Xi Tian, Jun Wang, Ze Wang
Cancer Medicine. 2026-09-01
Press Mentions
HMN 2025: How Kidney Cancer Drug Shows Promise Against Dangerous Calcium Imbalance Caused by TumorsOctober 19th, 2025- UTSW Builds AI-Driven System to Improve Data CollectionJuly 28th, 2025
- HMN 2025: How Cancer Cells Exploit Various Pathway to Assemble Antioxidant Lipids and Evade Cell DemiseJune 14th, 2025
Grant Support
- Leveraging First Mouse Model Reproducing Human Translocation Renal Cell Carcinoma to Investigate Molecular MechanismsUT SOUTHWESTERN MEDICAL CENTER2026–2031
- University of Texas Southwestern Medical Center SPORE in Kidney CancerUT SOUTHWESTERN MEDICAL CENTER2016–2027
- Specialized Program of Research Excellence (SPORE)NIH/NCI2016–Present
Committees
- Chair, Scientific Advisory Board, National Kidney Cancer Academy 2020 - Present
- Chair, Congressionally Directed Medical Research Program – Kidney Cancer Research Program 2017 - 2018
Professional Memberships
- Member
- Member
- American Society for Clinical Investigation - ASCIMember
Other Languages
- Spanish
External Links
- Kidney Cancer Programhttp://www.utsouthwestern.edu/kidneycancer
- Brugarolas Labhttp://www.brugarolaslab.com
- Kidney Cancer SPOREhttps://trp.cancer.gov/spores/kidney.htm
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
